Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Furthermore, vitamin D deficiency has become a worldwide health issue.

Few supplementation guidelines mention calcifediol treatment, despite being the direct precursor of calcitriol and the biomarker of vitamin D status.

Who Took Part

The study group was 303 patients.

PubMed tags the participants as women only.

A total of 303 patients were enrolled, of whom 298 were included in the intention-to-treat (ITT) population.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

What Was Measured

The subject headings attached to it are Calcifediol, Cholecalciferol, Dietary Supplements, Postmenopause, Vitamin D and Vitamin D Deficiency.

The authors tagged it with the keywords CLINICAL TRIALS.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 303 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2021 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.